Pipeline: Expanding the Potential of Raviset®
Beyond Endometriosis: A Broader Vision for Women’s Health
Raviset® is not just a treatment - it's a scalable platform for uterine disorders including AUB, Dysmenorrhea, and additional prevalent conditions that affect billions of women worldwide.
After successfully demonstrating Raviset®’s efficacy for this debilitating condition, we are already working to expand its indications to address a broader range of uterine disorders. By building on the proven success of our therapy, we aim to deliver innovative, non-hormonal solutions for several critical conditions affecting women’s health.
The 505(b)(2) Pathway
The Regulatory Shortcut
Following regulatory approval for endometriosis, Foraviset will utilize the FDA’s 505(b)(2) pathway for future indications. This approach allows us to build on Raviset®’s existing safety data, reducing development time and cost while advancing our vision of Raviset® as a platform therapy for chronic uterine disorders.
A TRANSFORMATIVE VISION FOR WOMEN’S HEALTH
Raviset® is not just a therapy - it is the cornerstone of a paradigm shift in women’s health. By broadening its indications to include these critical conditions, FORAVISET is advancing its mission to deliver safe, effective, and life-changing solutions for millions of women globally.